COMMENTARY
OPEN ACCESS
Abstract
New 2016 ACR/EULAR classification criteria for primary Sjogren’s syndrome (SS) have been developed and endorsed by the ACR. The newly proposed criteria include simple-to-perform items.
April 19, 2017
April 14, 2017
Vitamin D deficiency and interleukin-17 relationship in severe obstructive sleep apnea–hypopnea syndrome
| ORIGINAL ARTICLE | ||||
| Year : 2017 | Volume : 12 | Issue : 2 | Page : 107-113 | ||||
| Sonia Toujani1, Wajih Kaabachi2, Meriem Mjid1, Kamel Hamzaoui2, Jouda Cherif1, Majed Beji1 1 Department of Basic Sciences, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia 2 Unit Research 12SP15 “Homeostasis and Cell Dysfunction”, Abderrahman Mami Hospital, Ariana, Tunisia Correspondence Address: Sonia Toujani Department of Basic Sciences, Faculty of Medicine of Tunis, University of Tunis El Manar Tunisia  DOI: 10.4103/atm.ATM_301_16 | ||||
Purpose: We aimed to assess Vitamin D (VD) abnormalities in patients with severe obstructive sleep apnea–hypopnea syndrome (OSAHS), to study its association with clinical and polygraphic data, and to correlate VD levels with interleukin-17 (IL-17).
Methods: Ninety-two patients with severe OSAHS were consecutively enrolled between September 2014 and February 2016 and compared to age-, sex-, and body mass index (BMI)-matched controls. Anthropometric parameters and medical history were collected. The serum levels of VD and IL-17 were determined by radioimmunoassay and enzyme-linked immunosorbent assay, respectively. | ||||
Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study
Available online 5 April 2017
Open Access
Highlights
- •
- First report of Seqirus IIV4 in children aged 5–17 years.
- •
- Immunogenicity of Seqirus IIV4 was noninferior to a US-licensed comparator IIV4.
- •
- Fever rates were similar for both vaccines in children 5–8 years and 9–17 years.
Abstract
Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study
BMJ 2017; 357 doi: https://doi.org/10.1136/bmj.j1415
Cite this as: BMJ 2017;357:j1415
Akbar K Waljee, assistant professor1 2 3 4, Mary A M Rogers, research associate professor2 4 5, Paul Lin, statistican2,Amit G Singal, associate professor6, Joshua D Stein, associate professor2 7 8, Rory M Marks, associate professor 9,John Z Ayanian, professor2 5 8, Brahmajee K Nallamothu, professor 1 2 4 10
Author affiliations
Correspondence to: A K Waljee awaljee@med.umich.edu
Abstract
Objective To determine the frequency of prescriptions for short term use of oral corticosteroids, and adverse events (sepsis, venous thromboembolism, fractures) associated with their use.
April 1, 2017
Study of nasal exhaled nitric oxide levels in diagnosis of allergic rhinitis in subjects with and without asthma
ORIGINAL RESEARCH
Sy Duong-Quy,1–3 Thuc Vu-Minh,4 Thong Hua-Huy,1 Tram Tang-Thi-Thao,3 Khiet Le-Quang,3 Dinh Tran-Thanh,3 Nhu Doan-Thi-Quynh,3 Nhat-Nam Le-Dong,5 Timothy J Craig,2 Anh-Tuan Dinh-Xuan1
1Department of Respiratory Physiology, Cochin Hospital, Paris Descartes University, Sorbonne Paris Cité, Paris, France; 2Department of Medicine, Penn State University, Hershey, PA, USA; 3Bio-Medical Research Center, Lam Dong Medical College, Dalat, 4Department of Immuno-Allergology, ENT National Institute, Hanoi, Vietnam; 5Department of Pulmonology, St Elisabeth Hospital, Namur, Belgium
Background: The measure of fractional exhaled nitric oxide (FENO) in the airways is a useful tool to guide the diagnosis and titration of inhaled corticosteroids in patients with asthma. However, its role in diagnosis of allergic rhinitis (AR), especially in subjects with asthma, is not well established.
Objective: To study the cutoff of nasal FENO in the diagnosis of subjects with AR and AR-asthma compared to age-matched subjects without AR or asthma and its correlations with the clinical and functional characteristics.
1Department of Respiratory Physiology, Cochin Hospital, Paris Descartes University, Sorbonne Paris Cité, Paris, France; 2Department of Medicine, Penn State University, Hershey, PA, USA; 3Bio-Medical Research Center, Lam Dong Medical College, Dalat, 4Department of Immuno-Allergology, ENT National Institute, Hanoi, Vietnam; 5Department of Pulmonology, St Elisabeth Hospital, Namur, Belgium
Background: The measure of fractional exhaled nitric oxide (FENO) in the airways is a useful tool to guide the diagnosis and titration of inhaled corticosteroids in patients with asthma. However, its role in diagnosis of allergic rhinitis (AR), especially in subjects with asthma, is not well established.
Objective: To study the cutoff of nasal FENO in the diagnosis of subjects with AR and AR-asthma compared to age-matched subjects without AR or asthma and its correlations with the clinical and functional characteristics.
March 29, 2017
Japanese guidelines for allergic diseases 2017
Editorial
Invited Review Articles
Review Series: Japanese Guidelines for Allergic Diseases 2017
March 28, 2017
March 24, 2017
Persistent asthma phenotype related with late-onset, high atopy, and low socioeconomic status in school-aged Korean children
Received: 19 October 2016
Accepted: 16 February 2017
Published: 23 February 2017
Abstract
Background
Treatment guidelines for asthma have been established based on asthma severity; there are limitations in the identification of underlying pathophysiology and prediction of prognosis in heterogeneous phenotypes of asthma. Although the complex interactions between environmental and genetic factors affect the development and progression of asthma, studies on asthma phenotypes considering environmental factors are limited. This study aimed to identify asthma phenotypes using latent class analysis including environmental factors in school-age children.
March 21, 2017
Microbiome in atopic dermatitis
Uwe Wollina
Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany
Abstract: Atopic dermatitis (AD) is a common chronic inflammatory skin disease affecting ~10–20% of the general population. AD is characterized by disturbances in epidermal barrier function and hyperactive immune response. Recently, changes in the skin and intestinal microbiome have been analyzed in more detail. The available data suggest a link between disturbed skin microbiome and course of the disease.
March 18, 2017
Systematic review of pathways for the delivery of allergy services
Objectives The incidence and prevalence of allergies worldwide has been increasing and allergy services globally are unable to keep up with this increase in demand. This systematic review aims to understand the delivery of allergy services worldwide, challenges faced and future directions for service delivery.
March 17, 2017
March 15, 2017
Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils
Open Access
Abstract
Introduction
Asthma with adult onset and elevated blood eosinophils is a difficult-to-treat subgroup. This post hoc analysis evaluated reslizumab, an anti-interleukin-5 monoclonal antibody, in patients with late-onset eosinophilic asthma.
Methods
Data from two 52-week placebo-controlled trials of reslizumab IV 3 mg/kg every 4 weeks in patients aged 12–75 years with inadequately controlled asthma, ≥1 asthma exacerbation within 12 months, and screening blood eosinophils ≥400/μL (NCT01287039/NCT01285323) were stratified by age of asthma onset (- 40 or ≥40 years). Annual clinical asthma exacerbation rates, change in lung function, and patient-reported outcomes were analyzed.
Results
273 patients with late-onset asthma (placebo, n = 130; reslizumab, n = 143) and 658 with early-onset asthma (placebo, n = 336; reslizumab, n = 322) were included. Baseline demographics were similar between groups. The interaction between age at onset of asthma and effect of reslizumab on asthma exacerbations was statistically significant (p = 0.0083). Compared with placebo, reslizumab produced a 75% relative reduction in asthma exacerbations in patients with late-onset asthma (rate ratio [RR] 0.25; 95% confidence interval [CI], 0.16, 0.40), substantially larger than the reduction in earlier onset patients (RR 0.58; 95% CI, 0.44, 0.76). Similar findings were observed for other measures of asthma, including forced expiratory volume in 1 s (FEV1). The adverse event profile of reslizumab was similar in patients with early- or late-onset asthma.
Conclusions
Compared with placebo, reslizumab produced larger reductions in asthma exacerbations and larger improvements in lung function in patients with late versus early-onset asthma.
Subscribe to:
Posts (Atom)